FindTrial
Sign In

Xeomin®

BIOLOGICAL6 trials

Sponsors

Merz North America, Inc., Merz Pharmaceuticals GmbH, Wake Forest University Health Sciences, Huons Co., Ltd., ATGC Co., Ltd.

Conditions

BlepharospasmCervical DystoniaGlabellar Frown LinesGlabellar LinesStroke

Phase 2

Phase 2 of HU-045 in Glabellar Lines
CompletedNCT05298449
Huons Co., Ltd.Glabellar Lines
Start: 2022-03-28End: 2023-04-25Updated: 2023-07-05

Phase 3

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
NCT05623410
ATGC Co., Ltd.Glabellar Frown Lines
Start: 2022-10-11End: 2023-06-10Updated: 2023-02-03
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
RecruitingNCT06205797
Huons BiopharmaGlabellar Lines
Start: 2024-06-20End: 2025-03-31Target: 312Updated: 2024-10-03

Phase 4

Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex
CompletedNCT01486264
Merz Pharmaceuticals GmbHCervical Dystonia
Start: 2012-01-20End: 2016-03-29Updated: 2022-10-27
Xeomin® and Gait Related Mobility After Stroke
RecruitingNCT04908423
Wake Forest University Health SciencesStroke
Start: 2021-10-19End: 2027-04-30Target: 20Updated: 2025-11-25

Unknown Phase

Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States
CompletedNCT01287247
Merz North America, Inc.Blepharospasm, Cervical Dystonia
Start: 2011-02-28End: 2013-04-30Updated: 2015-04-10

Related Papers

Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study.
2022-03-146 citations